Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England
Paul R Ward1, Peter R Noyce2, Antony S St Leger3
1School of Health and Related Research, University of Sheffield, England, UK; 2School of Pharmacy and Pharmaceutical Sciences, University of Manchester, England, UK; 3School of Epidemiology and Health Sciences, University of Manchester, England, UK
Aim: To explore the relationship between actual and expected general medical practitioner (GP) practice prescribing rates for statins, angiotensin converting enzyme (ACE) inhibitors, and beta-blockers.
Background: There is a growing body of literature highlighting inequities in GP practice prescribing rates for many drug therapies. The equity of prescribing is of central importance in the area of therapeutics since it explores the interface between those patients who should and those who actually do receive a drug therapy.
Setting: Four primary care trusts (PCTs 1–4) in the North West of England, including 132 GP practices.
Methods: Actual and expected prescribing rates for statins, beta-blockers, and ACE inhibitors were specifically developed for each GP practice.
Results: There were no statistically significant correlations between actual and expected prescribing rates in PCT2 and PCT3, although in PCT1 there were statistically significant correlations for statins (0.286, p < 0.05) and ACE inhibitors (0.381, p < 0.01). In PCT4, correlations were moderate to high for beta-blockers (0.693, p < 0.01), and moderate for statins (0.541, p < 0.05) and ACE inhibitors (0.585, p < 0.01). Scatterplots highlighted large variations between individual GP practices (both within and between PCTs) in terms of the relationship between actual and expected prescribing rates.
Conclusion: This paper highlights variability between PCTs and GP practices in terms of the relationship between actual and expected prescribing rates. The findings from this paper may further advance the suggestion of inequities in prescribing rates for coronary heart disease (CHD) drugs, and studies such as this may be repeated in different therapeutic areas, healthcare settings, and countries.
Keywords: prescribing rates, equity, coronary heart disease, statins, beta-blockers, ACE inhibitor
Readers of this article also read:
Published Date: 16 April 2014
Pontillo D, Patruno N
Published Date: 20 January 2014
Interaction of recombinant and native Cav2.3 E-/R-type voltage-gated Ca2+ channels with the molecular chaperone Hsp70 [Corrigendum]
Radhakrishnan K, Krieger A, Tevoufouet EE, Dietz GP, Nagel F, Bähr M, Hescheler J, Schneider T
Published Date: 17 January 2014
Soosay Raj TA, Smith AM, Moore AS
Published Date: 6 November 2013
Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R
Published Date: 4 July 2013
Intervention for improving the appropriateness of physician orders for oral medications in geriatric VIP patients during the journey to JCI accreditation
Zhu LL, Zhou Q
Published Date: 28 May 2013
Stewart MW, Stewart ML
Published Date: 31 December 2012
Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP
Published Date: 30 March 2012
Schneider EW, Johnson MW
Published Date: 16 September 2011
Eduardo Pimenta, Suzanne Oparil
Published Date: 19 May 2009